Federal Circuit applied Amgen v. Sanofi, 598 U.S. 594 (2013)in deciding that claims 1-4, 19 and 20 of Baxalta's hemophilia patent, U.S. Patent 7,033,590 (‘590)...

Effective March 29, 2024, the U.S. Patent and Trademark Office (USPTO) issued a final rule to revise 37 C.F.R. §§ 90.2, 90.3, and 2.145 by updating how the following documents are to be filed with the USPTO Director...

The United States Patent and Trademark Office (USPTO) today announced a collaborative deferred-fee provisional patent application pilot program for inventions that combat COVID-19.

On Wednesday, July 1, 2020, the USPTO issued a release stating: The United States Patent and Trademark Office (USPTO) today announced plans for the Patent Trial and Appeal Board (PTAB)...

On June 15, 2023, the U.S. Patent and Trademark Office (USPTO) issued a final rule on the filing of a Patent Term Adjustment (PTA) statement regarding an Information Disclosure Statement (IDS).

To accelerate innovation in the health and medical fields, the USPTO published a Federal Register Notice announcing a fifth extension of its Cancer Immunotherapy Pilot Program.

On June 9, 2022, the USPTO issued updated guidance on the use of applicant admitted prior art (AAPA) in IPR proceedings, expanding upon a similar memorandum issued under prior Director Iancu.

On April 30, 2024, the USPTO published a Request for Comments on the future impact of publications by generative AI on the issue of prior art. Previously, the USPTO has consistently come down against generative AI.

The U.S. Patent and Trademark Office (USPTO) announced that it is temporarily extending the After Final Consideration Pilot Program 2.0 (AFCP 2.0) through December 14, 2024...

The USPTO will issue the registrations electronically under the electronic signature of the Director and with a digital seal, which will authenticate the registration.

Beginning July 1, the USPTO will accept new international applications to the IP5 Patent Cooperation Treaty (PCT) Collaboration Search and Examination Pilot (CS&E).

In Samsung Electronics America, Inc. v. Prisua Engineering Corp., the Fed. Cir. confirmed that, outside of the context of a motion to amend, the PTAB cannot cancel claims for indefiniteness in an IPR proceeding.

On April 28, 2021, Chief ALJ Charles E. Bullock issued the public version of Order No. 10 (dated April 16, 2021) granting-in-part Complainant EMD Serono, Inc.'s...

A bipartisan group of senators sponsored a bill this week—the Biologic Patent Transparency Act, S. 659—aimed at making patent information associated with biologics easier to identify and easing the approval process ...

On June 21, 2022, the Federal Circuit acting on a request for panel rehearing in the decision by the Federal Circuit in Novartis v. Accord Health Care, Inc., 21 F.4th 1362 (Fed. Cir. 2022), affirming...

The key point is that representations made in an IPR as to claim scope can provide a basis for a dismissal on the pleadings.

New USPTO Director Andrei Iancu provided the Intellectual Property Track plenary lecture at the 2018 BIO International Convention last week.

On July 14, 2021, the ITC issued a Notice of Investigation in Certain Silicon Photovoltaic Cells and Modules With Nanostructures, and Products Containing the Same (Inv. No. 337-TA-1271).

On October 29, 2021, the ITC issued a Notice of Investigation in Certain Barcode Scanners, Mobile Computers With Barcode Scanning Capabilities, Scan Engines, and Components Thereof (Inv. No. 337-TA-1285).

Understanding "At Least One Of A And B"